# ELEVANCE HEALTH, INC. (ELV) FY2025 Q1 P&L / Income Statement

- Company: ELEVANCE HEALTH, INC. (ELV)
- Period: 2025-01-01 to 2025-03-31
- Filing: Q1 FY2025 10-Q, filed 2025-04-22, accession number 0001156039-25-000057
- Page: https://plicit.ai/financials/elv/fy2025-q1-income-statement
- Chart image: https://plicit.ai/charts/elv-fy2025-q1-income-statement-sankey.png

## Chart details: Revenue by Product and Service (3 categories)

Income statement for 2025-01-01 through 2025-03-31. View: Product and service (3 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 48,891,000,000 US dollars
- **Total expenses**: 46,094,000,000 US dollars
- **Operating profit (calculated)**: 2,797,000,000 US dollars
- **Other income (expense), net (calculated)**: 0 US dollars
- **Income before income tax expense**: 2,797,000,000 US dollars
- **Income tax expense**: 613,000,000 US dollars
- **Net income**: 2,184,000,000 US dollars
- **Total operating revenue**: 48,765,000,000 US dollars
- **Net investment income**: 590,000,000 US dollars
- **Benefit expense**: 35,312,000,000 US dollars
- **Cost of products sold**: 4,983,000,000 US dollars
- **Operating expense**: 5,300,000,000 US dollars
- **Amortization of other intangible assets**: 155,000,000 US dollars
- **Interest expense**: 344,000,000 US dollars
- **Revenue before reconciliation (calculated)**: 49,355,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- **Net losses on financial instruments**: negative 464,000,000 US dollars. Reported reconciliation to consolidated revenue.

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
- Of which attributable to ELEVANCE HEALTH, INC.: $2.18 B; to noncontrolling interests: $1.00 M.